Funding Round attributes
On January 24, 2025, Springbok Analytics, a company specializing in AI-driven muscle health analysis, announced the successful completion of a $5 million Series A funding round. The round was led by Transition Equity Partners, LLC (TEP), with additional investments from the National Basketball Association, Cartan Capital, Boston Global (AUS), and other strategic partners.
The company offers three AI-powered muscle health scan options—Lower Extremity, Core, and Full Body—ranging from 10 to 35 minutes of total imaging time. In addition to delivering population benchmarks for muscle health, the platform provides advanced analyses of tendons, bone, scar tissue, and edema, making it a comprehensive muscle health solution.
The recent FDA clearance is a key achievement that highlights the value of Springbok's technology, accelerates future product development, and opens up commercial opportunities in healthcare, including visibility to reimbursement, benefiting athletes at every level and the general public's health and wellness.
Springbok's platform is advancing multiple fields. In life sciences, it enhances clinical trials and research aimed at improving therapies for musculoskeletal conditions. For elite sports, it provides athletes and trainers with precise, data-driven insights to optimize performance and recovery. The company is also addressing the growing demand for longevity solutions, equipping individuals with actionable insights to better manage muscle health as they age.
Other strategic investors in this funding round include TitletownTech, Anthropy Partners, Getty Performance Science, CAV Angels, and Alumni Ventures.
This investment will enable Springbok Analytics to advance its mission to improve muscle health analysis and expand its impact across clinical care, research, and health. The company remains committed to delivering innovative solutions that empower patients, providers, and researchers in the attainment of precision medicine.
